Strategic partnerships Protalix has active or recent collaboration ties with major players like Pfizer for taliglucerase alfa and Chiesi Farmaceutici for pegunigalsidase alfa, plus a new integration with Secarna Pharmaceuticals. This indicates a proven openness to co-development and commercial partnerships that can be leveraged to co-market new or expanded indications.

Expanded pipeline The company is advancing multiple plant cell expressed therapeutics (pegunigalsidase alfa, alidornase alfa PRX 110, PRX 115, PRX 119, among others). This breadth creates opportunities to position Protalix as a manufacturing and development partner for niche or orphan/rare disease programs seeking innovative expression platforms.

Platform leverage ProCellEx is their proprietary plant cell-based expression system with FDA approvals and industrial-scale capability. Potential customers in biotech and mid-size pharma seeking scalable, cost-effective production of recombinant proteins may be interested in outsourcing or technology licensing to accelerate timelines.

Global commercialization With existing global development and commercialization partnerships and listings on NYSE American and TASE, Protalix demonstrates distribution readiness. This can be attractive to investors and brands seeking international market access for rare-disease biologics and plant-based therapeutics.

Executive access Recent leadership changes including a new Chief Financial Officer and ongoing investor engagement indicate a focus on strategic financing and governance, signaling a company open to strategic deals, capital-efficient collaborations, and clarity for potential co-development or licensing opportunities.